Genincode moving towards 'a number of important milestones'

Genincode stated these milestones were expected to accelerate its commercial programme to lift the standard of care for cardiovascular disease by enabling "more precise patient diagnosis" and "risk stratification" to improve preventative care.

The AIM-listed firm also highlighted that it was still preparing for the US launch of its Cardio inCode product in 2022.

Chief executive Matthew Walls said: "Since admission in July, we have made solid progress in delivering the key milestones set out in our business plan.

"The business is developing swiftly and we are increasing our investment in key resources and expertise to take advantage of growth opportunities opening to us and strengthening our Board to include a greater US market presence, awareness, and expertise to reflect our long-term goals."

As of 1135 GMT, Genincode shares were up 5.26% at 40.0p.